Evoke Pharma Inc: Nasdaq/NYSE listing notice — Nasdaq grants Evoke Pharma extension to Nov 20, 2023 to meet equity requirement

Evoke Pharma Inc

Nasdaq extended deadline to Nov 20, 2023 to regain minimum $2.5M stockholders' equity.
Company had stockholders' equity of $2.1M as of Mar 31, 2023, below the $2.5M requirement.
Evoke submitted compliance plan on July 7, 2023; extension requires public evidence of compliance.
Failure to comply by 10-K filing for Dec 31, 2023 could result in delisting from Nasdaq Capital Market.
Company may appeal any delisting determination to a Hearings Panel, but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evoke Pharma Inc received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

July 19, 2023, Nasdaq notified the Company that it has granted the Company an extension until November 20, 2023 to regain compliance. Under the terms of the extension, the Company must provide to the Nasdaq staff a publicly available report that evidences such compliance and otherwise comply with conditions included in the extension notice. If the Company fails to evidence compliance upon filing the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission and Nasdaq, the Company may be subject to delisting from the Nasdaq Capital Mar

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-033755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.